Latest news
Iconovo signs agreement for development of inhaled oxytocin in ICOone for maternal health
Lund, December 21, 2020. Iconovo AB (publ) today announced that the company has signed a development agreement with Monash University for the development…
Iconovo’s collaboration with Stevanato marches on
Biostock published December 9th an article about Iconovo that can be found in its entirety below
Since entering a collaboration with the Italian healthcare…
Press releases
Jun 03, 2022, 15:57
News
IR
English
Corporate Information
Other Corporate Information
Jun 01, 2022, 07:52
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
May 23, 2022, 10:25
News
IR
Swedish
Corporate Information
Other Corporate Information
May 17, 2022, 13:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
May 02, 2022, 13:30
News
IR
English
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
Swedish
Corporate Information
Other Corporate Information
May 02, 2022, 07:30
News
IR
English
Corporate Information
Other Corporate Information
Apr 29, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q1
Apr 19, 2022, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 12, 2022, 08:45
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 29, 2022, 13:00
News
IR
English
Corporate Information
Other Corporate Information
Mar 25, 2022, 16:45
News
IR
Swedish
Regulatory
MAR
Corporate Information
Sales
Order
Feb 21, 2022, 09:15
News
IR
English
Corporate Information
Other Corporate Information
Feb 18, 2022, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Feb 09, 2022, 10:30
News
IR
English
Corporate Information
Other Corporate Information
Feb 09, 2022, 10:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se